4-[2-[6-[[2-(3,4-Dihydroxyphenyl)-2-hydroxyethyl]amino]hexylamino]-1-hydroxyethyl]benzene-1,2-diol;hydrochloride | 4323-43-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-[2-[6-[[2-(3,4-Dihydroxyphenyl)-2-hydroxyethyl]amino]hexylamino]-1-hydroxyethyl]benzene-1,2-diol;hydrochloride
• CAS: 4323-43-7
• 化学式: C22H33ClN2O6
• 分子量: 457.0
• InChiKey: BIVISKUNLSLUDP-UHFFFAOYSA-N

物化性质

• 熔点：
  197.5-198°

计算性质

• 辛醇/水分配系数(LogP)：
  2.44
• 重原子数：
  31
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  145
• 氢给体数：
  9
• 氢受体数：
  8

文献信息

• 1,3-Bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
  申请人：——

  公开号：US20030232877A1

  公开（公告）日：2003-12-18

  The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula 1 or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.

  这项发明涉及通式1的化合物、药物组合物和使用该化合物的方法，其中取代基在申请中定义。
• [EN] NOVEL SALT FORMS OF POORLY SOLUBLE PROBUCOL ESTERS AND ETHERS<br/>[FR] NOUVELLES FORMES DE SELS D'ETHERS ET D'ESTERS DE PROBUCOL FAIBLEMENT SOLUBLES
  申请人：ATHEROGENICS INC

  公开号：WO2004007423A1

  公开（公告）日：2004-01-22

  Organic amine salts of compounds of formula (I), and their pharmaceutically acceptable salts, and uses in medical therapy are provided.

  提供了公式（I）化合物的有机胺盐及其药用可接受的盐，并用于医学治疗。
• 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
  申请人：Atherogenics Pharmaceuticals, Inc.

  公开号：US20030236298A1

  公开（公告）日：2003-12-25

  It has been discovered certain 1,3-bis-(substituted-phenyl)-2-propen-1-ones, including compounds of formula (I) inhibit the expression of VCAM-1, and thus can be used to treat a patient with a disorder mediated by VCAM-1. Examples of inflammatory disorders that are mediated by VCAM-1 include, but are not limited to arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.

  已经发现了某些1,3-双-(取代苯基)-2-丙烯-1-酮，包括公式(I)化合物抑制VCAM-1的表达，因此可用于治疗受VCAM-1介导的疾病的患者。VCAM-1介导的炎症性疾病的例子包括但不限于关节炎、哮喘、皮炎、囊性纤维化、移植后晚期和慢性实体器官排斥、多发性硬化症、系统性红斑狼疮、炎症性肠病、自身免疫性糖尿病、糖尿病视网膜病变、鼻炎、缺血再灌注损伤、血管成形术后再狭窄、慢性阻塞性肺疾病（COPD）、肾小球肾炎、格雷夫斯病、胃肠道过敏、结膜炎、动脉粥样硬化、冠状动脉疾病、心绞痛和小动脉疾病。
• Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
  申请人：Meng Q. Charles

  公开号：US20060020038A1

  公开（公告）日：2006-01-26

  The invention relates to compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds, wherein the compounds are of the following Formulas: or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein the substituents are defined in the application. The invention further provides methods of treatment of inflammatory disorders by administering the compounds.

  本发明涉及化合物、包含该化合物的药物组成物以及使用该化合物的方法，其中该化合物的结构式为：或其药学上可接受的盐、酯或前药，其中取代基在申请中有定义。本发明进一步提供通过给予该化合物治疗炎症性疾病的方法。
• Chalcone derivatives and their use to treat diseases
  申请人：Ni Liming

  公开号：US20060189549A1

  公开（公告）日：2006-08-24

  The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.

  本发明涉及一般式化合物、药物组合物及使用该一般式化合物或其药学上可接受的盐或酯的方法，其中取代基在申请中定义。